文献速递浆细胞疾病

携带17p缺失的高危初诊多发性骨髓瘤患者的治疗模式与临床结局:一项观察性多中心回顾性研究

Treatment patterns and clinical outcomes in high-risk newly diagnosed multiple myeloma patients carrying the 17p deletion: An observational multi-center retrospective study.
PubMed 文献 · Am J Hematol · 2018-04-28

该观察性多中心回顾性研究纳入2008年1月至2016年1月8个中心连续60例经FISH证实携带17p缺失的初诊多发性骨髓瘤患者,多数接受含硼替佐米诱导,过半行自体造血干细胞移植,30%经临床试验、获取项目或私人保险早期获得新型药物。诱导后总缓解率85%,可移植组94%、不可移植组75%;中位总生存43个月,中位无进展生存11个月,可移植组19个月、不可移植组7个月。尽管自体移植和新型药物带来改善,17p缺失患者预后仍较差。

要点

  • 诱导后总缓解率85%,可移植组94% vs 不可移植组75%,后续治疗线缓解率下降,64%达到≥非常好的部分缓解。
  • 中位总生存43个月;中位无进展生存11个月,可移植组19个月 vs 不可移植组7个月。
  • 早期获得新型药物者总生存59个月;自体移植与不可移植患者总生存59.7个月 vs 28.7个月。

核心结论

  • 尽管自体造血干细胞移植和新型药物带来改善,17p缺失患者的预后仍较差,强调需要新的方法。

研究设计与样本

  • 观察性、回顾性、多中心研究,纳入8个参与中心2008年1月至2016年1月诊断的连续60例经荧光原位杂交(FISH)证实携带17p缺失的初诊多发性骨髓瘤患者。

主要发现

  • 多数患者接受含硼替佐米诱导,超过一半接受自体造血干细胞移植,30%的患者通过临床试验、获取项目或私人保险早期获得新型药物。
  • 诱导后总缓解率为85%,可移植(TE)患者为94%,不可移植(NTE)患者为75%,后续治疗线中下降,64%达到≥非常好的部分缓解(VGPR)。
  • 中位总生存(OS)为43个月;中位无进展生存(PFS)为11个月,TE患者为19个月,NTE患者为7个月。
  • 多因素分析显示,较高的M蛋白峰值、存在髓外疾病以及>50%的细胞携带del17p与不良PFS相关;自体造血干细胞移植和较高的血红蛋白与较长的PFS相关;早期获得新型药物的患者OS为59个月。
  • 年龄较大和较高的M蛋白峰值水平与不良OS相关,自体造血干细胞移植与有利的OS相关,NTE患者为59.7个月 vs 28.7个月。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Del17p is a genomic imbalance occurring in ∼7%-10% of myeloma at diagnosis newly diagnosed myeloma patients (NDMM) and comprises a poor prognostic factor. The goal of this study is to analyze real world data and outcomes among NDMM patients carrying 17p deletion. We report an observational, retrospective, multicenter study. Sixty consecutive patients diagnosed with multiple myeloma in the 8 participating centers diagnosed between 1/2008 and 1/2016 proven to carry 17p deletion by means of fluorescence in situ hybridization (FISH) were identified. Most received a bortezomib-based induction, over half underwent autologous hematopoietic cell transplantation (HCT); 30% of the patients gained early access to new novel agents via clinical trials, access programs or private insurance. Overall response rate (ORR) after induction was 85%; 94% for transplant eligible (TE); and 75% for transplant ineligible (NTE), and declined in subsequent treatment lines, 64% achieved ≥ VGPR. Median overall survival (OS) was 43 months; median progression free survival (PFS) was 11 months, 19 months for TE and 7 for NTE. In multivariate analysis: higher M-Spike, presence of extramedullary disease, and >50% of cells baring del17p were associated with adverse PFS; Autologous HCT and higher hemoglobin were associated with longer PFS; OS was 59 months for patients with early access to newer agents. Older age and higher M-Spike levels were associated with adverse OS, Autologous HCT was associated with favorable OS, 59.7 vs 28.7 months for NTE patients. Despite the improvement achieved with autologous HCT and new novel agents, the prognosis of patients with 17p deletion is still inferior, emphasizing the need for novel approaches.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Cohen YC, Saranga A, Gatt ME, et al. Treatment patterns and clinical outcomes in high-risk newly diagnosed multiple myeloma patients carrying the 17p deletion: An observational multi-center retrospective study. Am J Hematol. 2018. PMID: 29603773. doi:10.1002/ajh.25098

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。